Contribute Try STAT+ Today

Biogen (BIIB) is worth $12 billion more on Friday than it was the night before thanks to some surprising, if nebulous, new data on an in-development treatment for Alzheimer’s disease. The news is undoubtedly positive, but just how positive is a question that has all of biotech puzzling.

Here are the biggest questions about BAN2401, Biogen’s Eisai-partnered Alzheimer’s drug that is either the saving grace for a whole wing of neurology or a red herring of tortured data.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.